GH FREAK V.2.
Natural health product licensed in Canada
- Other names
- SLEEP FREAK
- Licence holder
- SAGA Sciences Canada, Inc.
- NPN or DIN-HM
- 80042572
- Status
- Active licence
- Licence date
- 30 May 2013
- Revision date
- 26 September 2023
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| N-acétyl-5-méthoxytryptamine Source : Mélatonine | 1 mg | Not calculated |
| Acide 3-pyridinecarboxylique Source : Niacine | 2 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Gélatine, Stéarate de magnésium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | minimum: 3 Capsule ; maximum: 5 Capsule | 1 day |
Uses authorised in Canada
Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule, e.g., shift-work and jet lag. Helps to reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people with delayed sleep phase disorder. Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
People sensitive to nicotinic acid may experience flushing of the skin that is generally mild and transient. Caffeine has been known to increase the effects of melatonin (e.g. drowsiness). Mild gastrointestinal symptoms (nausea, vomiting, or cramping) have been known to occur in which case, discontinue use. Rare allergic reactions have been known to occur in which case, discontinue use. Some people may experience drowsiness. Exercise caution if operating heavy machinery, driving a motor vehicle or involved in activities requiring mental alertness. Some people may experience diarrhea, nausea, vomiting and abdominal pain.
Source
Official Health Canada record, licence 80042572
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2023. Photograph the packaging to check whether it has changed. Photograph the packaging